[Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Tempest Therapeutics, Inc. director John D. Yee filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing shows no reported transactions, derivative positions, or holding entries at this time.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"director John D. Yee filed an initial Form 3, which is the required statement"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"initial Form 3, which is the required statement of beneficial ownership for new insiders"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

""reportingPersons": [{"name": "Yee John D.", "is_director": 1"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yee John D.

(Last) (First) (Middle)

118 LEXINGTON ROAD

(Street)

LINCOLN MASSACHUSETTS 01773

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2026

3. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This transaction is being reported late due to an inadvertent administrative oversight.

No securities are beneficially owned.

	/s/ John David Yee	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does John D. Yee's Form 3 filing mean for TPST investors?

The Form 3 shows John D. Yee is a director of Tempest Therapeutics and is now an insider. It reports no transactions or derivative positions, serving as a baseline ownership disclosure required by SEC rules.

Does the TPST Form 3 for John D. Yee show any stock purchases or sales?

No, the Form 3 for John D. Yee reports no buy, sell, acquire, or dispose transactions. All transaction-related counts, including exercises and gifts, are shown as zero in the transaction summary.

Are there any options or derivatives reported for John D. Yee in TPST's Form 3?

No, the derivative summary in the Form 3 is empty. This indicates there are no reported stock options, warrants, or other derivative securities associated with John D. Yee in this initial statement.

What insider role does John D. Yee have at Tempest Therapeutics (TPST)?

The Form 3 identifies John D. Yee as a director of Tempest Therapeutics, Inc. He is not listed as an officer or 10% owner in the structured data of this filing.

Does the TPST Form 3 include any footnote disclosures for John D. Yee?

The structured data shows a placeholder for footnotes but no substantive text. There are no additional disclosures about voting power, indirect ownership, or trading plans in the provided information.